MYLAN-VERAPAMIL 80 MG — DIN 02237921
VERAPAMIL HYDROCHLORIDE : 80 MG · MYLAN PHARMACEUTICALS ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MYLAN-VERAPAMIL?
MYLAN-VERAPAMIL 80 MG contains VERAPAMIL HYDROCHLORIDE : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02237921, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Apr-2024. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MYLAN-VERAPAMIL used for?
MYLAN-VERAPAMIL (Verapamil hydrochloride) Tablets are indicated in: Chronic stable angina of effort, Angina resulting from coronary artery spasm, Obstructive hypertrophic cardiomyopathy, where surgery is not otherwise indicated, Atrial fibrillation or flutter with rapid ventricular response not otherwise controllable with digitalis preparations, Follow-up treatment to the use of injectable verapamil in paroxysmal supraventricular tachycardia, and in the treatment of mild to moderate essential hypertension.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Verapamil cost around the world?
Verapamil is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 15 | 19 | ZAR███.██ |
| United States | acquisition | 3 | 13 | USD███.██ |
| Australia | ex-manufacturer | 6 | 12 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 12 | 12 | EUR███.██ |
| Romania | max producer price | 5 | 6 | RON███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Slovakia | categorised final price | 5 | 5 | EUR███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
81 pack listings across 59 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Verapamil pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Verapamil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Verapamil, across 53 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 5 | 2 | APO-VERAP SR, APO-VERAP TAB 80MG, APO-VERAP TABLET 120MG | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 8 | 1 | MYLAN-VERAPAMIL, MYLAN-VERAPAMIL SR | Sourceable in Canada |
| BGP PHARMA ULC | 3 | 1 | ISOPTIN SR | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | VERAPAMIL HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| NU-PHARM INC | 5 | 0 | NU-VERAP SR, NU-VERAP TAB 120MG, NU-VERAP TAB 80MG | No marketed DIN |
| PRO DOC LIMITEE | 5 | 0 | PRO-VERAPAMIL SR, VERAPAMIL TAB 80MG, VERAPAMIL-120 TAB | No marketed DIN |
| ABBOTT LABORATORIES, LIMITED | 3 | 0 | ISOPTIN INJ 2.5MG/ML, ISOPTIN TAB 120MG, ISOPTIN TAB 80MG | No marketed DIN |
| PFIZER CANADA ULC | 3 | 0 | COVERA-HS, VERAPAMIL HYDROCHLORIDE INJECTION USP | No marketed DIN |
| RECRO GAINESVILLE LLC | 3 | 0 | VERELAN | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | NOVO-VERAMIL, NOVO-VERAMIL SR | No marketed DIN |
| PENTAPHARM LTD. | 2 | 0 | PENTA-VERAPAMIL - 120MG, PENTA-VERAPAMIL - 80MG | No marketed DIN |
| TARO PHARMACEUTICALS INC | 2 | 0 | TARO-VERAPAMIL TAB 120MG, TARO-VERAPAMIL TAB 80MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 80 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Verapamil |
|---|---|
| ATC code | C08DA01 |
| AHFS class | 88:30.00* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02237921 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2237921 |
| Brand name | MYLAN-VERAPAMIL |
| Generic / active ingredient | VERAPAMIL HYDROCHLORIDE : 80 MG |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | C08DA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C08DA |
| Current status | CANCELLED POST MARKET |
| Status date | 11-Apr-2024 |
| Original market date | 1999-09-17 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Dosage must be individualized. Administered orally. In patients with hepatic insufficiency, a decreased dosage should be used.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Complicated MI, severe CHF, cardiogenic shock, severe hypotension, 2nd/3rd degree A-V block, sick sinus syndrome, marked bradycardia, hypersensitivity, AF/flutter with accessory bypass tract.
Warnings and precautions
Negative inotropic effect may cause heart failure; slows A-V conduction; causes dose-related suppression of S-A node; caution in hepatic/renal impairment; monitor liver enzymes.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 53 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-VERAP TAB 80MG | 80 MG | TABLET | APOTEX INC | MARKETED | 00782483 |
| APO-VERAP TABLET 120MG | 120 MG | TABLET | APOTEX INC | MARKETED | 00782491 |
| ISOPTIN SR | 120 MG | TABLET (EXTENDED-RELEASE) | BGP PHARMA ULC | MARKETED | 01907123 |
| MYLAN-VERAPAMIL SR | 120 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02210347 |
| VERAPAMIL HYDROCHLORIDE INJECTION USP | 2.5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 02166739 |
| ALTI-VERAPAMIL - 120MG | 120 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00867373 |
| ALTI-VERAPAMIL - 80MG | 80 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00867365 |
| APO-VERAP SR | 120 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | 02246893 |
| APO-VERAP SR | 180 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | 02246894 |
| APO-VERAP SR | 240 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | 02246895 |
2 · Same class — other molecules in ATC C08DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Verapamil | ALTI-VERAPAMIL - 120MG · ALTI-VERAPAMIL - 80MG · APO-VERAP SR · APO-VERAP TAB 80MG · +29 more | 53 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C08D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C08DB | Diltiazem | 175 | 75 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MYLAN-VERAPAMIL called?
The same molecule, Verapamil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Isoptin SR | Latin | Australia, South Africa |
| Cordilox SR | Latin | Australia |
| FIBROCARD LP | Latin | Morocco |
| Isoptin | Latin | Australia |
| Isoptin ICHS retard | Latin | Slovakia |
| Sandoz Verapamil | Latin | South Africa |
| Vasomil Injection | Latin | South Africa |
| VeraHexal | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.